The company’s lead asset, CTX-712, is in phase 1 clinical trials for advanced, relapsed or refractory malignant cancers. It is an orally available, selective, small-molecule inhibitor of CDC ...
Bitwise announced the Bitwise Trendwise Bitcoin and Treasuries Rotation Strategy ETF (BITC) on Friday, a fund that combines the Bitwise Bitcoin Strategy Optm Roll ETF (BITC), Bitwise Ethereum ...
“We are pleased to have raised additional substantial capital, which allows us to focus on advancing the final activities required for NDA submission of our lead asset, CTx-1301, which is ...